Investigating the inhibition of cytochrome P450 isoform 1A1 by açai berry (Euterpe oleracea) extracts using a bioassay guided fractionation approach

UNCG Author/Contributor (non-UNCG co-authors, if there are any, appear on document)
Davis Earl Collins (Creator)
The University of North Carolina at Greensboro (UNCG )
Web Site:
Gregory Raner

Abstract: Xenobiotic metabolism is an important process within the human body, as it alters large, foreign, hydrophobic molecules and prepares them for excretion. This process is largely carried out in the liver and is accomplished by a superfamily of heme-containing enzymes, termed the Cytochrome P450’s. Each individual P450 has a certain specificity for the substrates it may metabolize, but these enzymes are non-selective in nature and may catalyze the metabolism of a wide variety of substrates. Due to this characteristic of P450 – mediated metabolism, pharmaceuticals when taken concomitantly may possibly interfere with one another’s metabolism, which can lead to adverse drug reactions. This can also be true for natural product constituents that have been consumed as a part of one’s dietary intake. Consumption of the acai berry (Euterpe oleracea) has grown quite rapidly in recent years as it contains a high concentration of antioxidant molecules, and has also been marketed as a weight loss supplement. Although it appears to benefit one’s health and longevity, the acai berry has not been characterized in terms of its effect on P450 – mediated metabolism. Utilizing an activity guided fractionation scheme, acai berry extracts were assayed in CYP1A1 and CYP1A2 enzyme reactions to determine constituents responsible for enzyme inhibition.

Additional Information

Language: English
Date: 2016
Acai Berry, CYP1A1
Cytochrome P-450 $x Inhibitors
Enzyme inhibitors
Acai palm

Email this document to